Advanced HCC: Emerging molecular therapies

Minerva Gastroenterologica e Dietologica

Volumn 58, Issue 1, 2012, Pages 25-34

  Finn, R S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Carcinoma; Hepatocellular; Molecular targeted therapy

Indexed keywords

ADI PEG 20; ARGININE DEIMINASE; BEVACIZUMAB; BRIVANIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; LINIFANIB; ORANTINIB; RAMUCIRUMAB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADVANCED CANCER; BONE MARROW SUPPRESSION; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CYTOTOXICITY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; FATIGUE; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; INJECTION SITE DISCOMFORT; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SKIN IRRITATION; TREATMENT INDICATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

ANTIBODIES, MONOCLONAL; BENZENESULFONATES; CALIFORNIA; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HEPATECTOMY; HUMANS; INCIDENCE; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PREVALENCE; PROTEIN KINASE INHIBITORS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME; WORLD HEALTH;

EID: 84860300461     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76. (Pubitemid 46890874)
3. [No authors listed]. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-5.
4. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-28. (Pubitemid 15228292)
5. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38:207-15. (Pubitemid 36527122)
6. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38.
7. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
8. Mulcahy MF. Management of hepatocellular cancer. Curr Treat Options Oncol 2005;6:423-35. (Pubitemid 41684222)
9. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36. (Pubitemid 43112690)
10. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9. (Pubitemid 26079803)
11. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-403. (Pubitemid 32496976)
12. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007;7:2587-96. (Pubitemid 47561609)
13. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009;49:453-9.
14. Bouza C, Lopez-Cuadrado T, Alcázar R, Saz-Parkinson Z, Amate JM. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol 2009;9:31.
15. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-42. (Pubitemid 36152543)
16. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
17. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40.
18. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-72. (Pubitemid 46202316)
19. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300. (Pubitemid 46630787)
20. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
21. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667-76. (Pubitemid 39265589)
22. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008;68:6779-88.
23. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006;12:410-6.
24. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007;45:42-52. (Pubitemid 46144363)
25. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
26. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
27. Cheng AKY, Lin D, Park J, Kudo M, Qin S, Omata M et al. Phase III trial of sunitnib versus sorafenib in advanced hepatocellular carcinoma. J Clin Oncol 29:abstr 4000, 2011
28. Zhu AX, Raymond E. Early development of sunitinib in hepatocellular carcinoma. Expert Rev Anticancer Ther 2009;9:143-50.
29. Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009;10:794-800.
30. Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A et al. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 2010;15:285-92.
31. Ayers M, Fargnoli J, Lewin A, Wu Q, Platero JS. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Cancer Res 2007;67:6899-906. (Pubitemid 47105537)
32. Huang X, Yu C, Jin C, Kobayashi M, Bowles CA, Wang F et al. Ectopic activity of fibroblast growth factor receptor 1 in hepatocytes accelerates hepatocarcinogenesis by driving proliferation and vascular endothelial growth factor-induced angiogenesis. Cancer Res 2006;66:1481-90. (Pubitemid 43259929)
33. Ogasawara S, Yano H, Iemura A, Hisaka T, Kojiro M. Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines. Hepatology 1996;24:198-205. (Pubitemid 26249434)
34. Sawey ET, Chanrion M, Cai C, Wu G, Zhang J, Zender L et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell 2011;19:347-58.
35. Allen E, Walters IB, Hanahan D: Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res 2011;17:5299-310.
36. Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011;17:1973-83.
37. Finn RS, Park JW, Kang YK Baudelet C, Walters I. Time-to-progression sub-analysis of second-line treatment with brivanib after failure of prior antiangiogenic therapy in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma. Presented at the Am Assoc for the Study of Liver Disease Annual Meeting, 2009. abstract
38. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ et al. Preclinical activity of ABT-869, a multi-targeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006;5:995-1006. (Pubitemid 43724600)
39. Toh HC CP, Carr BI, Knox JJ, Gill S, Qian J, Qin Q et al. Linifanib in advanced Hepatocellular Carcinoma (HCC) patients: A phase 2 trial. Hepatology 2010;52:1777.
40. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
41. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23.
42. Sieghart W, Fuereder T, Schmid K, Cejka D, Werzowa J, Wrba F et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation 2007;83:425-32. (Pubitemid 46667846)
43. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135:1972-83, 1983 e1-11.
44. Huynh H, Chow KP, Soo KC, Toh HC, Choo SP, Foo KF et al. RAD001 (everolimus) inhibits tumor growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med 2009;13:1371-80
45. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Thng CH et al. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med 2009;13:2673-83.
46. Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 2011;117:5094-102.
47. Chen L, Shiah SH, Chen CY, Lin YJ, Lin PW, Su WC et al. Randomized, phase I, and pharmacokinetic study of RAD 001, an mTOR inhibitor, in patients with advanced hepatocellular carcinoma. J Clin Oncol 2009;27:abstr 4587.
48. Zhu AX FR, Mulahy MF, Gurtler JS, Sun W, Schwartz JD, Rojas P et al. A phase II study of ramucirumab as first-line monotherapy in patients with advanced hepatocellular J Clin Oncol 2010;28:abstr 4083.
49. Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 2010;28:2220-6.
50. Kanai F, Yoshida H, Tateishi R, Sato S, Kawabe T, Obi S et al. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2011;67:315-24.
51. Arai Y, Inaba T, Yamamoto TKanai F, Aramaki T, Tanaka T et al. A randomized Phase II study of TSU-68 in patients (Pts) with hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE). J Clin Oncol 2010;28:4030.
52. Lopez-Chavez A, Giaccone G. Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer. Nat Rev Clin Oncol 2010;7:360-2.
53. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-6.
54. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843-50.
55. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27:672-80, 2009
56. Tol J, Koopman M, Cats A, Scroggin C, Hagenstad C, Spigel D et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72.
57. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010;304:2154-60.
58. Finn RS PR, Yau T, Klumpen H, Chen L, Kang Y, Kim T et al. Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2011;29:abstr 4074.